DK2027156T3 - Hepatocytvækstfaktor (HGF)bindingsprotein - Google Patents

Hepatocytvækstfaktor (HGF)bindingsprotein

Info

Publication number
DK2027156T3
DK2027156T3 DK07795599.5T DK07795599T DK2027156T3 DK 2027156 T3 DK2027156 T3 DK 2027156T3 DK 07795599 T DK07795599 T DK 07795599T DK 2027156 T3 DK2027156 T3 DK 2027156T3
Authority
DK
Denmark
Prior art keywords
hgf
growth factor
binding protein
hepatocyte growth
hepatocyte
Prior art date
Application number
DK07795599.5T
Other languages
Danish (da)
English (en)
Inventor
S Kirk Wright
William M Winston
May Han
Lyne Breault
Jie Lin
Bijan Etemad-Gilbertson
Christine Knuehl
Jeno Gyuris
Arnold Horwitz
Original Assignee
Aveo Pharmaceuticals Inc
Xoma Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aveo Pharmaceuticals Inc, Xoma Technology Ltd filed Critical Aveo Pharmaceuticals Inc
Application granted granted Critical
Publication of DK2027156T3 publication Critical patent/DK2027156T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
DK07795599.5T 2006-06-02 2007-06-01 Hepatocytvækstfaktor (HGF)bindingsprotein DK2027156T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81071406P 2006-06-02 2006-06-02
US86050906P 2006-11-21 2006-11-21
PCT/US2007/012939 WO2007143090A2 (en) 2006-06-02 2007-06-01 Hepatocyte growth factor (hgf) binding proteins

Publications (1)

Publication Number Publication Date
DK2027156T3 true DK2027156T3 (da) 2011-04-26

Family

ID=38802077

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07795599.5T DK2027156T3 (da) 2006-06-02 2007-06-01 Hepatocytvækstfaktor (HGF)bindingsprotein

Country Status (20)

Country Link
US (5) US7649083B2 (enExample)
EP (2) EP2027156B9 (enExample)
JP (3) JP4686634B2 (enExample)
KR (1) KR101196060B1 (enExample)
AR (1) AR061171A1 (enExample)
AT (1) ATE495195T1 (enExample)
AU (1) AU2007254942B2 (enExample)
BR (1) BRPI0712222B1 (enExample)
CA (1) CA2654025C (enExample)
CY (1) CY1111714T1 (enExample)
DE (1) DE602007011923D1 (enExample)
DK (1) DK2027156T3 (enExample)
IL (2) IL195037A (enExample)
MX (1) MX2008014829A (enExample)
NO (1) NO345476B1 (enExample)
NZ (1) NZ573818A (enExample)
PL (1) PL2027156T3 (enExample)
PT (1) PT2027156E (enExample)
SG (1) SG158112A1 (enExample)
WO (1) WO2007143090A2 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA015363B1 (ru) 2003-07-18 2011-06-30 Эмджен Инк. Агенты, специфически связывающие фактор роста гепатоцитов, и их применение
US7649083B2 (en) 2006-06-02 2010-01-19 Aveo Pharmaceuticals, Inc. Hepatocyte growth factor (HGF) binding antibody
MX2008015138A (es) * 2006-06-02 2009-01-28 Aveo Pharmaceuticals Inc Proteinas de union al factor de crecimiento de hepatocitos (fch).
US20080233660A1 (en) * 2007-03-23 2008-09-25 Mu Bioteknik Ab Solid phase labeling method
ES2694018T3 (es) 2007-07-02 2018-12-17 Oncomed Pharmaceuticals, Inc. Composiciones y métodos para el tratamiento y el diagnóstico del cáncer
SG186017A1 (en) 2007-11-30 2012-12-28 Kalobios Pharmaceuticals Inc Antibodies to the pcrv antigen of pseudomonas aeruginosa
MY155049A (en) * 2008-03-14 2015-08-28 Allergan Inc Immuno-based botolinum toxin serotype a activity assay
KR101590495B1 (ko) 2008-05-29 2016-02-01 갤럭시 바이오테크, 엘엘씨 염기성 섬유모세포 성장 인자에 대한 모노클로날 항체
DK3290052T3 (da) 2008-11-07 2020-02-03 Galaxy Biotech Llc Monoklonale antistoffer mod fibroblastvækstfaktorreceptor 2
WO2010119991A2 (en) 2009-04-17 2010-10-21 Takeda Pharmaceutical Company Limited Novel method of treating cancer
EP2588107A1 (en) 2010-07-01 2013-05-08 Takeda Pharmaceutical Company Limited COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
SG10201408229WA (en) 2010-08-31 2015-02-27 Genentech Inc Biomarkers and methods of treatment
EP3252076B1 (en) 2011-01-14 2019-09-04 The Regents Of The University Of California Diagnostic use of antibodies against ror-1 protein
WO2013012747A1 (en) 2011-07-15 2013-01-24 Oncomed Pharmaceuticals, Inc. Rspo binding agents and uses thereof
CA2847245A1 (en) 2011-09-09 2013-03-14 Amgen Inc. Use of c-met protein for predicting the efficacy of anti-hepatocyte growth factor ("hgf") antibodies in esophageal and gastric cancer patients
AU2012312515A1 (en) 2011-09-19 2014-03-13 Genentech, Inc. Combination treatments comprising c-met antagonists and B-raf antagonists
CN104854132A (zh) 2012-07-13 2015-08-19 昂考梅德药品有限公司 Rspo3结合剂及其用途
WO2014128235A1 (en) 2013-02-22 2014-08-28 F. Hoffmann-La Roche Ag Methods of treating cancer and preventing drug resistance
US9481725B2 (en) * 2013-03-14 2016-11-01 Alderbio Holdings, Llc Antibodies to HGF and compositions containing
US9732150B2 (en) * 2013-03-14 2017-08-15 Alderbio Holdings Llc Therapeutic use of antibodies to HGF
TW201444868A (zh) * 2013-03-14 2014-12-01 Alder Biopharmaceuticals Inc Ｈｇｆ抗體及其組成物
US9062104B2 (en) * 2013-03-14 2015-06-23 Alderbio Holdings Llc Therapeutic use of antibodies to HGF
BR112015025549A2 (pt) * 2013-04-07 2017-10-10 Bioex Therapeutics Inc anticorpo contra o receptor do fator de crescimento epidérmico
WO2015031578A1 (en) * 2013-08-28 2015-03-05 Abbvie Inc. Hgf assay
EP3122900A1 (en) 2014-03-24 2017-02-01 F. Hoffmann-La Roche AG Cancer treatment with c-met antagonists and correlation of the latter with hgf expression
KR20170005016A (ko) 2014-05-23 2017-01-11 제넨테크, 인크. MiT 바이오마커 및 그의 사용 방법
CA2958144A1 (en) * 2014-08-15 2016-02-18 Oncomed Pharmaceuticals, Inc. Rspo1 binding agents and uses thereof
WO2016044295A1 (en) 2014-09-16 2016-03-24 Oncomed Pharmaceuticals, Inc. Treatment of fibrotic diseases
WO2017070567A1 (en) * 2015-10-21 2017-04-27 The Research Foundation For The State University Of New York Klebsiella pneumoniae antibodies and methods to treat klebsiella pneumoniae infections
AU2020327537A1 (en) 2019-08-12 2022-03-03 Interna Technologies B.V. New treatments involving miRNA-193a
US20230136088A1 (en) 2020-02-28 2023-05-04 Interna Technologies B.V. miRNA-193a for Promoting Immunogenic Cell Death
CN116234814A (zh) * 2020-08-28 2023-06-06 江苏恒瑞医药股份有限公司 用于降低异源多肽末端异质性的信号肽
KR20240004937A (ko) 2021-05-05 2024-01-11 이매틱스 바이오테크놀로지스 게엠베하 Bma031 항원 결합 폴리펩타이드

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US6893625B1 (en) 1986-10-27 2005-05-17 Royalty Pharma Finance Trust Chimeric antibody with specificity to human B cell surface antigen
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
WO1993011794A1 (en) 1991-12-13 1993-06-24 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
CA2372813A1 (en) 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US6066718A (en) 1992-09-25 2000-05-23 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
US6498144B1 (en) 1993-10-18 2002-12-24 North Shore - Long Island Jewish Research Institute Use of scatter factor to enhance angiogenesis
US5837676A (en) 1993-10-18 1998-11-17 Long Island Jewish Medical Center Use of scatter factor to enhance angiogenesis
US5707624A (en) 1994-06-03 1998-01-13 The Regents Of The University Of Michigan Treatment of Kaposi's sarcoma by inhibition of scatter factor
EP1972194A1 (en) 1996-12-03 2008-09-24 Amgen Fremont Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
US6872518B2 (en) 1997-09-22 2005-03-29 University Of Rochester Methods for selecting polynucleotides encoding T cell epitopes
WO2001034650A1 (en) 1999-11-09 2001-05-17 The Government Of The United States Of America, As Represented By The Secretary, Department Of Heatlh And Human Services Hgf-sf monoclonal antibody combinations
AU2002368077B2 (en) 2001-07-12 2010-03-04 Jefferson Foote Super humanized antibodies
US7220410B2 (en) 2003-04-18 2007-05-22 Galaxy Biotech, Llc Monoclonal antibodies to hepatocyte growth factor
US20040208876A1 (en) * 2003-04-18 2004-10-21 Kim Kyung Jin Monoclonal antibodies to hepatocyte growth factor
EA015363B1 (ru) * 2003-07-18 2011-06-30 Эмджен Инк. Агенты, специфически связывающие фактор роста гепатоцитов, и их применение
KR100556660B1 (ko) * 2003-11-11 2006-03-10 국립암센터 Ｈｇｆ의 중화가능 에피토프 및 이에 결합하는 중화 항체
RU2007146986A (ru) 2005-06-02 2009-06-27 ГЭЛЭКСИ БАЙОТЕК, ЭлЭлСи (US) Способы лечения опухолей головного мозга с использованием антител
AR059922A1 (es) 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
US7649083B2 (en) 2006-06-02 2010-01-19 Aveo Pharmaceuticals, Inc. Hepatocyte growth factor (HGF) binding antibody
MX2008015138A (es) 2006-06-02 2009-01-28 Aveo Pharmaceuticals Inc Proteinas de union al factor de crecimiento de hepatocitos (fch).
KR100829972B1 (ko) 2006-07-14 2008-05-16 재단법인서울대학교산학협력재단 항-ｈｇｆ/ｓｆ 인간화 항체 및 이의 제조방법
KR100881825B1 (ko) * 2007-07-27 2009-02-03 주식회사 하이닉스반도체 반도체 소자 및 그 제조 방법

Also Published As

Publication number Publication date
IL219654A0 (en) 2012-06-28
US20100173362A1 (en) 2010-07-08
NO20085421L (no) 2009-02-27
US7943344B2 (en) 2011-05-17
KR101196060B1 (ko) 2012-11-01
MX2008014829A (es) 2009-01-29
BRPI0712222A2 (pt) 2012-01-10
JP2011072318A (ja) 2011-04-14
NZ573818A (en) 2011-09-30
EP2361934A3 (en) 2011-11-02
EP2027156A2 (en) 2009-02-25
PL2027156T3 (pl) 2011-06-30
US7649083B2 (en) 2010-01-19
JP2009539347A (ja) 2009-11-19
AU2007254942A1 (en) 2007-12-13
US20130203963A1 (en) 2013-08-08
JP2013090632A (ja) 2013-05-16
ATE495195T1 (de) 2011-01-15
US20110229462A1 (en) 2011-09-22
HK1129395A1 (en) 2009-11-27
AU2007254942A8 (en) 2009-02-05
AR061171A1 (es) 2008-08-06
AU2007254942A2 (en) 2009-05-28
SG158112A1 (en) 2010-01-29
KR20090027226A (ko) 2009-03-16
CA2654025A1 (en) 2007-12-13
US8273355B2 (en) 2012-09-25
US9096664B2 (en) 2015-08-04
EP2027156B9 (en) 2011-03-30
AU2007254942B2 (en) 2011-10-27
DE602007011923D1 (de) 2011-02-24
JP5735476B2 (ja) 2015-06-17
CA2654025C (en) 2016-08-02
US8580930B2 (en) 2013-11-12
WO2007143090A3 (en) 2008-03-13
NO345476B1 (no) 2021-02-22
EP2027156B1 (en) 2011-01-12
US20140178935A1 (en) 2014-06-26
IL195037A0 (en) 2011-08-01
EP2361934A2 (en) 2011-08-31
JP4686634B2 (ja) 2011-05-25
BRPI0712222B1 (pt) 2021-10-13
US20080108565A1 (en) 2008-05-08
IL195037A (en) 2015-08-31
WO2007143090A2 (en) 2007-12-13
PT2027156E (pt) 2011-04-18
CY1111714T1 (el) 2015-10-07

Similar Documents

Publication Publication Date Title
ATE495195T1 (de) Hepatocytenwachstumsfaktor-(hgf-)bindungsprotei e
IL195038A0 (en) Hepatocyte growth factor binding proteins
NO20201120A1 (no) Bindingsvirkninger
NO20082564L (no) Hepatosyttvekstfaktorintronfusjonsproteiner
LT3339445T (lt) Baltymai, suryšantys interleukiną 13
DK2046826T3 (da) Exendin-fusionsproteiner
EP1776134A4 (en) C-MET KINASE BINDING PROTEINS
DK3118221T3 (da) Proteiner
SI2126093T1 (sl) Izboljšanje priprave proteinov
CY2016029I1 (el) Πρωτεϊνες συνδεσης αντιγονου προς προπρωτεϊνη κονβερτασης σουμπτιλισινης κεχιν τυπου 9(pcsk9)
DK1864998T3 (da) Bindingsmolekyler
DK1999154T3 (da) Fremstillede heterodimere proteindomæner
EP2215246A4 (en) PROTEIN SCAFFOLDS
CU23869B1 (es) Anticuerpos anti-esclerostina y proteínas funcionales
DK2094292T3 (da) Salpeteroxid-blokeret tværbundet tetramerisk hæmoglobin
EP1784219A4 (en) STABILIZING FORMULATIONS
BRPI0814971A2 (pt) Proteína
DK1809660T3 (da) Thymus-specifikt protein
ZA200809483B (en) Hepatocyte growth factor (HGF) binding proteins
PL1871804T3 (pl) Przeciwciała wiążące CCX-CKR2
GB0610140D0 (en) Protein stability
AT500473B8 (de) Inkubator
AT504183A3 (de) Skibindungssystem
FI20050547A0 (fi) Side
ITCN20060002A1 (it) Imbiellaggio martino